Combinations of Herceptin with pertuzumab, or T-DM1 and mTOR inhibitors added to an aromatase inhibitor are new therapeutic approaches for the treatment of HER2+ breast cancers [276]. This evidence concerns the gene ERBB2 and breast cancer.